InflaRx to Report Full Year 2025 Results on March 19, 2026

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) will report fourth quarter and full year 2025 results on March 19, 2026 before the market opens; no conference call is planned.

The company is developing izicopan (INF904), an oral C5aR inhibitor, and vilobelimab, an IV anti-C5a antibody, and maintains offices in Jena, Munich and Ann Arbor.

News Market Reaction – IFRX

+1.96%

2 alerts

+1.96% News Effect

+4.0% Peak Tracked

-6.9% Trough Tracked

+$1M Valuation Impact

$70M Market Cap

0.4x Rel. Volume

On the day this news was published, IFRX gained 1.96%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.0% during that session. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $70M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: March 19, 2026 Reporting period: Fourth quarter and full year 2025 Clinical phases: Phase 1 and Phase 2a +3 more

6 metrics

Earnings release date March 19, 2026 Q4 and full year 2025 results before market open

Reporting period Fourth quarter and full year 2025 Scheduled financial and operating results

Clinical phases Phase 1 and Phase 2a Izicopan has shown potential in Phase 1 and Phase 2a studies

Founding year 2007 InflaRx founding date

Europe contact phone +49 89-210 2280 MC Services Europe contact for InflaRx

U.S. contact phone +1-339-832-0752 MC Services U.S. contact for InflaRx

Market Reality Check

Price: $0.9100 Vol: Volume 66,842 vs 20-day a...

low vol

$0.9100 Last Close

Volume Volume 66,842 vs 20-day average 181,933 (relative volume 0.37). low

Technical Price 0.962 is trading below the 200-day MA of 1.07 and about 50.41% under the 52-week high.

Peers on Argus

IFRX is up 3.44% while key biotech peers like SRZN, MGNX, HLVX and XBIT show neg...

1 Up

IFRX is up 3.44% while key biotech peers like SRZN, MGNX, HLVX and XBIT show negative moves. Momentum scanner flags only one peer (ATOS) moving up, suggesting today’s action in IFRX is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Conference participation	Neutral	-0.3%	Participation in Leerink Global Healthcare Conference with fireside chat and meetings.
Jan 29	Investor conferences	Neutral	+1.3%	Multiple February investor conference appearances highlighting lead programs.
Jan 08	Strategic refocus	Negative	-9.2%	Capital-efficient strategy with ~30% workforce reduction and cost cuts.
Dec 30	Clinical data update	Neutral	+0.0%	Updated Phase 3 vilobelimab analyses in pyoderma gangrenosum after early termination.
Dec 11	Drug naming & data	Positive	-2.9%	INN assignment for izicopan with supportive PK/PD and Phase 2a signals.

Pattern Detected

Recent IFRX news has generally produced modest price moves, with a mix of aligned reactions and one notable divergence on positive clinical branding news.

Recent Company History

Over the last several months, InflaRx has focused investor communication on conferences, strategic refocusing, and pipeline updates. A Jan 8, 2026 strategy shift and workforce reduction aligned with a sharper negative move, while routine conference participation in Jan–Feb 2026 produced only small reactions. The Dec 11, 2025 announcement of the international nonproprietary name for izicopan, alongside encouraging clinical signals, coincided with a negative price reaction, showing divergence. Overall, news flow has centered on capital-efficient execution and advancing izicopan and vilobelimab.

Market Pulse Summary

This announcement sets March 19, 2026 as the date for InflaRx’s Q4 and full year 2025 results, givin...

Analysis

This announcement sets March 19, 2026 as the date for InflaRx’s Q4 and full year 2025 results, giving a clear timeline for the next fundamental update. Investors may focus on how financials reflect the recent cost-cutting strategy, cash runway, and continued investment in izicopan and vilobelimab. Key items to watch include operating expenses, any guidance on trial plans, and confirmation of priorities for the company’s inflammation-focused pipeline.

Key Terms

complement system, anti-c5a, anti-c5ar, c5a receptor, +4 more

8 terms

complement system medical

"pioneering anti-inflammatory therapeutics by targeting the complement system"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

anti-c5a medical

"applying its proprietary anti-C5a and anti-C5aR technologies"

Anti-C5a is an antibody or small-molecule drug that blocks C5a, a naturally occurring protein that can trigger intense inflammation as part of the immune response; by neutralizing C5a the therapy aims to reduce harmful immune overreactions. For investors, anti-C5a candidates matter because positive clinical results can create new treatments for severe infections, autoimmune flares or inflammation-driven conditions, affecting a developer’s regulatory milestones, market potential and stock value—think of it as a medical brake on runaway inflammation.

anti-c5ar medical

"applying its proprietary anti-C5a and anti-C5aR technologies"

Anti-C5aR are drugs—often engineered antibodies or small molecules—that block the C5a receptor on immune cells, preventing a powerful immune signal (C5a) from triggering excessive inflammation. For investors, these therapies matter because they aim to calm harmful immune overreactions in conditions like severe infections or autoimmune diseases; success or failure in clinical trials and regulatory review greatly affects a drug’s commercial potential, development risk, and company valuation.

c5a receptor medical

"inhibitors of the complement activation factor C5a and its receptor, C5aR"

A C5a receptor is a protein on certain immune cells that senses the inflammatory signal called C5a, acting like a doorbell that summons and activates immune responders at sites of injury or infection. Investors care because drugs that block or modify this receptor can dial down damaging inflammation seen in conditions such as autoimmune disease, sepsis, or some lung disorders, making it a common target in pharmaceutical development and a potential value driver in drug pipelines.

monoclonal antibody medical

"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

pk/pd medical

"has shown promising PK/PD characteristics as well as therapeutic potential"

PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.

hidradenitis suppurativa medical

"developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS)"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

biopharmaceutical medical

"InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

AI-generated analysis. Not financial advice.

JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens. No conference call is planned.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When will InflaRx (IFRX) release its Q4 and full year 2025 results?

InflaRx will publish Q4 and full year 2025 results on March 19, 2026 before market open. According to InflaRx, the company will release financial and operating results that morning and will not host a conference call.

Will InflaRx (IFRX) hold an earnings call for the March 19, 2026 report?

No, InflaRx will not host an earnings conference call for the March 19, 2026 release. According to InflaRx, results will be released before market open and management did not schedule a live call or webcast.

What lead programs does InflaRx (IFRX) highlight ahead of the March 19, 2026 results?

InflaRx highlights izicopan (INF904) and vilobelimab as lead programs. According to InflaRx, izicopan is an oral C5aR inhibitor and vilobelimab is an IV anti-C5a antibody with demonstrated clinical activity.

How can investors contact InflaRx investor relations after the March 19, 2026 release?

Investors can contact InflaRx investor relations via Email: IR@inflarx.de or the MC Services contacts listed. According to InflaRx, regional phone numbers for Europe and the U.S. are provided for follow-up inquiries.

Where are InflaRx (IFRX) corporate offices located as noted in the March 12, 2026 notice?

InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. According to InflaRx, these locations support its research and corporate operations for its anti-inflammatory programs.